Labs and Groups

Bell Lab

Bell Lab

Publications

1.    Russo S, Giannoula Y, Feola S, Cerioni J, Hamdan F, Chiaro J, Thu Ha Dang A, Bottega P, Feodoroff M, Fusciello M, Stigzelius V, D’Amico C, Caiazza C, Antignani G, D’Alessio F, Sakalauskaite M, Petryk J, Bell JC, Ilkow CS, Grönholm M, Cerullo V. Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy.  J Immunother Cancer 2025 Nov 12;13(11); 13:e012138. doi:10.1136/jitc-2025-012138

2.    Barr T*, Jennings VA, Roundhill EA, Baugh RT, Yamrali M, Owston HE, McGonagle D, Giannoudis PV, Caplen NJ, Khan J, Bell JC,  Burchill SA, Errington-Mais F, Cook GP. Oncolytic Maraba virus MG1 mediates direct and natural killer cell-dependent lysis of Ewing sarcoma. Cancers (Basel)2025 Oct 14;17(20):3319.

3.    Klemets H, Bardoul A, Pelin A, Singaravelu R, Boileau M, Falls T,  Petryk J,  Marie-Claude Bourgeois-Daigneault M-C, Bell JC, Roy DG.  RNAi screen in tumor cells identifies artificial microRNAs that improve oncolytic virus replication (2025) Pharmaceuticals 2025, 18(5), 708.

4.    Jennings VA, Rumbold-Hall R, Migneco G, Barr T, Reilly K, Ingram N, St Hilare I, Heaton S, Alzamel N, Jackson D, Ralph C, Banerjee S, McNeish I, Bell JC, Melcher AA, Ilkow CS, Cook GP, Errington-Mais F. Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment (2024) Frontiers in Immunology  15:1500570. doi: 10.3389/fimmu.2024.1500570. 

5.    Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, Marotel M, Buchler A, Fadel S, Park MM, Fong-McMaster C, Crupi MF, Makinson OJ, Kurdieh R, Rezaei R, Dhillon HS, Ilkow CS, Bell JC, Harper ME, Rotstein BH, Auer RC, Vanderhyden BC, Sabourin LA, Bourgeois-Daigneault MC, Cook DP, Ardolino M. PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway (2024). Journal of Experimental Medicine 221(7):e20221721. doi: 10.1084/jem.20221721. 

6.    Antonova L, Paramanthan P, Falls T, Wedge ME, Mayer J, Sekhon HS, McPherson J, Denroche RE, Gallinger S, Bell JC, Ilkow CS, Chatterjee A. Molecular Characterization and Xenotransplantation of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) (2024) Cancers (Basel). 16(15):2721. doi: 10.3390/cancers16152721. 

7.    Ilkow CS, Bell JC. Optimizing oncolytic virus design: a "Swiss army knife" approach to create a systemically delivered therapeutic (2024) Signal Transduction and Targeted Therapy. 9(1):82. doi: 10.1038/s41392-024-01815-2. 

8.    Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy (2024) Nature Communications. 2024 15(1):7267. doi: 10.1038/s41467-024-51498-0. 

9.    Gujar S, Pol JG, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G, Bell JC. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy. (2024) Nature Protocols (9):2540-2570. doi: 10.1038/s41596-024-00985-1.

10.    Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T. Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses. (2024) Nature Biomedical Engineering. doi: 10.1038/s41551-024-01259-7. 

11.    Martin NT, Crupi MJF, Taha Z, Poutou J, Whelan JT, Vallati S, Petryk J, Marius R, Austin B, Azad T, Boulanger M, Burgess T, Sanders I, Victoor C, Dickinson BC, Diallo JS, Ilkow CS, Bell JC. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy. (2023) Pharmaceuticals (Basel) 16(5):709. doi: 10.3390/ph16050709. 

12.    Azad T, Rezaei R, Singaravelu R, Pelin A, Boulton S, Petryk J, Onsu KA, Martin NT, Hoskin V, Ghahremani M, Marotel M, Marius R, He X, Crupi MJF, Hoang HD, Nik-Akhtar A, Ahmadi M, Zamani NK, Golshani A, Alain T, Greer P, Ardolino M, Dickinson BC, Tai LH, Ilkow CS, Bell JC. Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. (2023) Nature Communications. 14(1):3035. doi: 10.1038/s41467-023-38651-x. 

13.    Whelan JT, Singaravelu R, Wang F, Pelin A, Tamming LA, Pugliese G, Martin NT, Crupi MJF, Petryk J, Austin B, He X, Marius R, Duong J, Jones C, Fekete EEF, Alluqmani N, Chen A, Boulton S, Huh MS, Tang MY, Taha Z, Scut E, Diallo JS, Azad T, Lichty BD, Ilkow CS, Bell JC. CRISPR-mediated rapid arming of poxvirus
vectors enables facile generation of the novel immunotherapeutic STINGPOX. (2023)  Frontiers in Immunology 13:1050250. doi: 10.3389/fimmu.2022.1050250. 

14.    Taha Z, Crupi MJF, Alluqmani N, Fareez F, Ng K, Sobh J, Lee E, Chen A, Thomson M, Spinelli MM, Ilkow CS, Bell JC, Arulanandam R, Diallo JS. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus (2023) Frontiers in Immunology. 14:1181014. doi: 10.3389/fimmu.2023.1181014. 

15.    Moulin C, Crupi MJF, Ilkow CS, Bell JC, Boulton S. Extracellular Vesicles and Viruses: Two Intertwined Entities. (2023) International Journal of Molecular  Science. 24(2):1036. doi: 10.3390/ijms24021036. 

16.    Boulton S, Poutou J, Gill R, Alluqmani N, He X, Singaravelu R, Crupi MJF, Petryk J, Austin B, Angka L, Taha Z, Teo I, Singh S, Jamil R, Marius R, Martin N, Jamieson T, Azad T, Diallo JS, Ilkow CS, Bell JC. (2023) A T cell-targeted multi- antigen vaccine generates robust cellular and humoral immunity against SARS- CoV-2 infection. (2023) Molecular Therapy Methods Clinical Development 31:101110. doi: 10.1016/j.omtm.2023.101110. 

17.    Boulton S, Crupi MJF, Singh S, Carter-Timofte ME, Azad T, Organ BC, He X, Gill R, Neault S, Jamieson T, Dave J, Kurmasheva N, Austin B, Petryk J, Singaravelu R, Huang BZ, Franco N, Babu K, Parks RJ, Ilkow CS, Olagnier D, Bell JC. Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development.(2023) Journal of Biological Chemistry 299(6):104749. doi: 10.1016/j.jbc.2023.104749. 

18.    Surendran A, Jamalkhah M, Poutou J, Birtch R, Lawson C, Dave J, Crupi MJF, Mayer J, Taylor V, Petryk J, de Souza CT, Moodie N, Billingsley JL, Austin B, Cormack N, Blamey N, Rezaei R, McCloskey CW, Fekete EEF, Birdi HK, Neault S, Jamieson TR, Wylie B, Tucker S, Azad T, Vanderhyden B, Tai LH, Bell JC, Ilkow CS. Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy lipid modulation of the tumor microenvironment.(2023) Frontiers in  Immunology 14:1099459. doi: 10.3389/fimmu.2023.1099459. 

19.    Angka L, Tanese de Souza C, Baxter KE, Khan ST, Market M, Martel AB, Tai LH, Kennedy MA, Bell JC, Auer RC. Perioperative arginine prevents metastases by accelerating natural killer cell recovery after surgery. (2022) Molecular Therapy. 30(10):3270-3283. doi: 10.1016/j.ymthe.2022.05.024. 

20.    Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, Bell JC. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.(2022)  Frontiers in  Immunology. 13:1029269. doi: 10.3389/fimmu.2022.1029269.